

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jay BUA

Title:

REDUCTION OF BREAST

DENSITY WITH 4-HYDROXY

TAMOXIFEN

Appl. No.:

10/734,644

Filing Date:

12/15/2003

Examiner:

B. Fetterolf

Art Unit:

1642

Confirmation

9030

Number:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima* facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months after filing an RCE.

RELEVANCE OF EACH DOCUMENT

U.S. 2004/0086552 is the U.S. equivalent of WO 02/03969, which was cited in the International Search Report of the PCT application corresponding to co-pending application US 2005/0032909.

The other listed U.S. patent applications are co-pending applications with the same assignee as the instant application (Laboratoires Besins International SA), except for US 2005/0158388, which is assigned to Laboratoires Besins International SA and Ascend Therapeutics, Inc., US 2005/0032910, which is assigned to Ascend Therapeutics, Inc. and Northwestern University and US 2003/0087885, which is assigned to Besins International Belgique.

The other listed references are of record in one or more of the co-pending applications.

US 2005/0031695 has been allowed, but a Request for Continued Examination (RCE) is being prepared to submit an Information Disclosure Statement (IDS). US 2003/0087885, US 2005/0032909, US 2005/0208139, US 2005/0032910, US 2005/0158388, and US 2005/0209340 have been rejected. US 2006/0105041 is awaiting examination.

The Notice of Allowance issued June 24, 2008. US 2005/0031695 (with Reasons for Allowance) is submitted herewith.

The Office Action rejecting claims in US 2005/0032909 also is submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

.)

Although Applicant believes that no fee is required, the Commissioner is hereby authorized to charge any additional fees which may be required to Deposit Account No. 19-0741.

Respectfully submitted,

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone:

(202) 295-4094

Facsimile:

(202) 672-5399

Courtenay C. Brinckerhoff

Attorney for Applicant

Registration No. 37,288